Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shionogi to Break from Long-Listed Drugs
April 5, 2010
- Korosho to Lift 14-Day Limit on Prescriptions of Thalidomide
April 5, 2010
- Hisamitsu Launches Fentanyl Transdermal System in the US
April 5, 2010
- Korosho Explains New Premium to Semi-Public Hospital Groups
April 5, 2010
- Research Funds Should Be Provided Based on Contracts: Dr Imamura
April 5, 2010
- Kitasato Univ. to Kick Off Global Clinical Research Center
April 5, 2010
- Place Top-Priority on Elimination of Bulk-Buying by Sum Value
April 5, 2010
- Keio Univ. to Promote Global Clinical Research
April 5, 2010
- All MRs from Eisai to Promote Oncology Products
April 5, 2010
- Korosho to Review Its Policy Re Clinical Trial Core Hospitals
April 5, 2010
- Sucampo Applies for Arbitration Regarding Amitiza Agreement with Takeda
April 5, 2010
- Ono Ties Up with BioSeek for Bioactive Lipid Drug Discovery
April 5, 2010
- Hyogo Prefecture to Start 3-Year Plan to Promote Use of Generics
April 5, 2010
- Taiyo to Improve Its Quality Assurance System
April 5, 2010
- RIKEN, Torii Jointly Develop Cedar Pollinosis Vaccine
April 5, 2010
- Daiichi Sankyo Espha to Establish Low-Cost Marketing System
April 5, 2010
- Once-Monthly Risedronate for Osteoporosis Enters PIII: Takeda, Ajinomoto
April 5, 2010
- Bayer Transfers Imaging Agent to I'rom
April 5, 2010
- Dabigatran Reduces Strokes More Than Warfarin in AF
April 5, 2010
- 13 Products, Including Takeda's Rozerem, Recommended for Approval
April 5, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…